Hypertrophic Cardiomyopathy: Clinical Trials

25 trials for Hypertrophic Cardiomyopathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 3 unknown, 2 recruiting, 2 terminated. 25 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 225Completed 17, Unknown 3, Recruiting 2, Terminated 2, Active not recruiting 1
Phase 34Completed 3, Terminated 1
Phase 11Recruiting 1

Follow Hypertrophic Cardiomyopathy: new trials by email Literature Review of Hypertrophic Cardiomyopathy trials Research Report on Hypertrophic Cardiomyopathy

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
HRS-1893 Tablet - Hypertrophic Cardiomyopathy
Phase 2RecruitingShandong Suncadia Medicine Co., Ltd.3002025-07-042025-09-10
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
EDG-7500 - Hypertrophic Cardiomyopathy
Phase 2Active not recruitingEdgewise Therapeutics, Inc.792024-04-112026-07-31
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
TN-201 - Hypertrophic Cardiomyopathy
Phase 1 / Phase 2RecruitingTenaya Therapeutics302023-08-102026-03-19
Role of Perhexiline in Hypertrophic Cardiomyopathy
Perhexiline, Placebo - Hypertrophic Cardiomyopathy
Phase 2UnknownFlinders University602020-12-012021-03-11
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
Trientine, Placebo - Hypertrophic Cardiomyopathy
Phase 2CompletedManchester University NHS Foundation Trust1542020-12-012025-09-29
Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
Lifestyle, Sacubitril/Valsartan - Hypertrophic Cardiomyopathy
Phase 2CompletedNewcastle University1682019-05-032022-11-28
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
Sacubitril/Valsartan, Lifestyle - Hypertrophic Cardiomyopathy
Phase 2 / Phase 3CompletedNewcastle-upon-Tyne Hospitals NHS Trust1682019-04-012022-05-09
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
mavacamten - Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Phase 2 / Phase 3CompletedBristol-Myers Squibb3142018-09-272026-02-20
The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
Metoprolol Succinate, Placebo oral capsule - Hypertrophic Cardiomyopathy
Phase 2CompletedSteen Hvitfeldt Poulsen302018-05-012021-03-29
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
mavacamten - Hypertrophic Cardiomyopathy
Phase 2CompletedBristol-Myers Squibb132018-04-262025-01-09
Hypertrophic Cardiomyopathy Symptom Release by BX1514M
Treatment BX1514M, Placebo, Walk distance test - Hypertrophic Cardiomyopathy
Phase 2CompletedUniversity Hospital, Bordeaux382015-10-072026-05-14
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Eleclazine, Placebo - Hypertrophic Cardiomyopathy
Phase 2 / Phase 3TerminatedGilead Sciences1722015-02-052018-09-24
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan, Placebo - Hypertrophic Cardiomyopathy
Phase 2CompletedCarelon Research2112014-03-012021-01-11
Trimetazidine Therapy in Hypertrophic Cardiomyopathy
Trimetazidine, Placebo capsule - Hypertrophic Cardiomyopathy
Phase 2UnknownUniversity College, London902012-04-012013-02-28
Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
Losartan, Placebo - Hypertrophic Cardiomyopathy
Phase 2CompletedHenning Bundgaard1302011-11-012014-07-09
Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
99mTc-NC100692 - Hypertrophic Cardiomyopathy, Acute Coronary Syndrome
Phase 2TerminatedOttawa Heart Institute Research Corporation1202011-05-012017-04-24
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
losartan, placebo - Hypertrophic Cardiomyopathy
Phase 2CompletedMassachusetts General Hospital202007-02-012013-09-05
Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
Perhexiline/Placebo - Hypertrophic Cardiomyopathy
Phase 2CompletedUniversity Hospital Birmingham442006-12-012010-11-04
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
Diltiazem, Placebo - Hypertrophic Cardiomyopathy
Phase 2 / Phase 3CompletedBrigham and Women's Hospital392006-01-012015-04-07
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
trans-right ventricular alcohol septal ablation (TRVASA) - Hypertrophic Cardiomyopathy
Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)122002-04-012008-03-04

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

Cardiomyopathy, Hypertrophic (25)  ·  Hypertrophy (3)  ·  Cardiomyopathies (2)  ·  Cardiomyopathy, Hypertrophic, Familial (2)  ·  Heart Failure (2)  ·  Acute Coronary Syndrome (1)  ·  Angina Pectoris (1)  ·  Arrhythmias, Cardiac (1)  ·  Cardiovascular Diseases (1)  ·  Cicatrix (1)  ·  Coronary Artery Disease (1)  ·  Coronary Disease (1)  ·  Death, Sudden (1)  ·  Dyspnea (1)  ·  Fibrosis (1)

Broader conditions

Aortic Stenosis, Subvalvular (25)  ·  Aortic Valve Disease (25)  ·  Aortic Valve Stenosis (25)  ·  Heart Valve Diseases (25)  ·  Cardiovascular Diseases (24)  ·  Heart Diseases (24)  ·  Cardiomyopathies (23)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Pathological Conditions, Anatomical (4)  ·  Pathologic Processes (3)  ·  Vascular Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Myocardial Ischemia (2)  ·  Arterial Occlusive Diseases (1)

Interventions

Losartan (2)  ·  MYK-461 (2)  ·  Perhexiline (2)  ·  sacubitril and valsartan sodium hydrate drug combination (2)  ·  Angiotensin Receptor Antagonists (1)  ·  Diltiazem (1)  ·  Ethanol (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Metoprolol (1)  ·  Trientine (1)  ·  Trimetazidine (1)  ·  Valsartan (1)  ·  candesartan (1)  ·  eleclazine (1)  ·  pirfenidone (1)

Sponsors

National Heart, Lung, and Blood Institute (NHLBI) (5)  ·  Bristol-Myers Squibb (2)  ·  Brigham and Women's Hospital (1)  ·  Carelon Research (1)  ·  Charles University, Czech Republic (1)  ·  Edgewise Therapeutics, Inc. (1)  ·  Flinders University (1)  ·  Gilead Sciences (1)  ·  Henning Bundgaard (1)  ·  Manchester University NHS Foundation Trust (1)  ·  Massachusetts General Hospital (1)  ·  Newcastle University (1)  ·  Newcastle-upon-Tyne Hospitals NHS Trust (1)  ·  Ottawa Heart Institute Research Corporation (1)  ·  Shandong Suncadia Medicine Co., Ltd. (1)

Countries

United States (13)  ·  United Kingdom (7)  ·  Denmark (3)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Australia (2)  ·  Canada (2)  ·  Czechia (2)  ·  Israel (2)  ·  Netherlands (2)  ·  Belgium (1)  ·  China (1)  ·  Poland (1)  ·  Portugal (1)

Top investigators

Carolyn Y Ho, MD (1)  ·  Carolyn Y. Ho, MD (1)  ·  Chris Miller (1)  ·  Djordje Jakovljevic, PhD (1)  ·  Dr Djordje G Jakovljevic (1)  ·  Joseph Selvanayagam (1)  ·  Martin Penicka, PhD (1)  ·  Michael A Fifer, MD (1)  ·  Michael Frenneaux, MD (1)  ·  Morten Kvistholm Jensen, MD, PhD (1)  ·  Perry M Elliott, MBBS MD (1)  ·  Rajiv Ananthakrishna (1)

Results publications

PMID 24621999, PMID 25533774, PMID 12957437, PMID 18403758, PMID 19074594, PMID 20837938, PMID 20921440, PMID 22075468, PMID 22932717, PMID 24361242, PMID 24674997, PMID 25176015, PMID 25533966, PMID 26661322, PMID 26874390, PMID 26898633, PMID 27590665, PMID 28306757, PMID 28547861, PMID 28662936, PMID 28912187, PMID 29249422, PMID 29321131, PMID 29754651, PMID 30725091, PMID 31813281, PMID 34556856, PMID 34915981, PMID 35450573, PMID 37137675, PMID 37672268, PMID 38176782, PMID 38591260, PMID 39087355, PMID 39217450, PMID 39302117, PMID 40042824, PMID 40340372, PMID 42455121, PMID 42636950, PMID 42858009, PMID 7641357

NIH funding

K23HL078901 (1), P50HL112349 (1)